Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database
Drug-induced ILD is emerging as an important safety issue, and physicians need to maintain a high index of suspicion of ILD in patients treated with a TKI.
Authors
- Simon P. Hart (ORCID: https://orcid.org/0000-0003-4606-9559)
- Devron R. Shah (ORCID: https://orcid.org/0000-0002-1860-9709)
- Dominic L. Sykes (ORCID: https://orcid.org/0000-0002-0925-7772)
Institutions
- Castle Hill Hospital (GB)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1007/s40801-025-00515-9
- Citations
- 1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52